These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Copy number gain of MYCN gene is a recurrent genetic aberration and favorable prognostic factor in Chinese pediatric neuroblastoma patients. Wang M; Zhou C; Cai R; Li Y; Gong L Diagn Pathol; 2013 Jan; 8():5. PubMed ID: 23320395 [TBL] [Abstract][Full Text] [Related]
4. MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma. Zhang S; Wei JS; Li SQ; Badgett TC; Song YK; Agarwal S; Coarfa C; Tolman C; Hurd L; Liao H; He J; Wen X; Liu Z; Thiele CJ; Westermann F; Asgharzadeh S; Seeger RC; Maris JM; Guidry Auvil JM; Smith MA; Kolaczyk ED; Shohet J; Khan J Cancer Lett; 2016 Feb; 371(2):214-24. PubMed ID: 26683771 [TBL] [Abstract][Full Text] [Related]
5. Detection of amplified DNA sequences by reverse chromosome painting using genomic tumor DNA as probe. Joos S; Scherthan H; Speicher MR; Schlegel J; Cremer T; Lichter P Hum Genet; 1993 Feb; 90(6):584-9. PubMed ID: 8383093 [TBL] [Abstract][Full Text] [Related]
6. MYCN is amplified during S phase, and c‑myb is involved in controlling MYCN expression and amplification in MYCN‑amplified neuroblastoma cell lines. Aygun N; Altungoz O Mol Med Rep; 2019 Jan; 19(1):345-361. PubMed ID: 30483774 [TBL] [Abstract][Full Text] [Related]
7. Somatic copy number alterations are associated with EGFR amplification and shortened survival in patients with primary glioblastoma. Muñoz-Hidalgo L; San-Miguel T; Megías J; Monleón D; Navarro L; Roldán P; Cerdá-Nicolás M; López-Ginés C Neoplasia; 2020 Jan; 22(1):10-21. PubMed ID: 31751860 [TBL] [Abstract][Full Text] [Related]
8. ALK is a MYCN target gene and regulates cell migration and invasion in neuroblastoma. Hasan MK; Nafady A; Takatori A; Kishida S; Ohira M; Suenaga Y; Hossain S; Akter J; Ogura A; Nakamura Y; Kadomatsu K; Nakagawara A Sci Rep; 2013 Dec; 3():3450. PubMed ID: 24356251 [TBL] [Abstract][Full Text] [Related]
9. Heterogeneity of MYCN amplification in neuroblastoma at diagnosis, treatment, relapse, and metastasis. Marrano P; Irwin MS; Thorner PS Genes Chromosomes Cancer; 2017 Jan; 56(1):28-41. PubMed ID: 27465929 [TBL] [Abstract][Full Text] [Related]
10. MYCN amplified neuroblastoma requires the mRNA translation regulator eEF2 kinase to adapt to nutrient deprivation. Delaidelli A; Negri GL; Jan A; Jansonius B; El-Naggar A; Lim JKM; Khan D; Oo HZ; Carnie CJ; Remke M; Maris JM; Leprivier G; Sorensen PH Cell Death Differ; 2017 Sep; 24(9):1564-1576. PubMed ID: 28574509 [TBL] [Abstract][Full Text] [Related]
11. Direct Targeting of Yoda H; Inoue T; Shinozaki Y; Lin J; Watanabe T; Koshikawa N; Takatori A; Nagase H Cancer Res; 2019 Feb; 79(4):830-840. PubMed ID: 30584073 [TBL] [Abstract][Full Text] [Related]
12. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma. Hallett RM; Seong AB; Kaplan DR; Irwin MS Mol Oncol; 2016 Nov; 10(9):1461-1472. PubMed ID: 27599694 [TBL] [Abstract][Full Text] [Related]
13. MIAT Is an Upstream Regulator of NMYC and the Disruption of the MIAT/NMYC Axis Induces Cell Death in Feriancikova B; Feglarova T; Krskova L; Eckschlager T; Vicha A; Hrabeta J Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33806217 [TBL] [Abstract][Full Text] [Related]
14. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma. Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123 [TBL] [Abstract][Full Text] [Related]
15. MYCN drives glutaminolysis in neuroblastoma and confers sensitivity to an ROS augmenting agent. Wang T; Liu L; Chen X; Shen Y; Lian G; Shah N; Davidoff AM; Yang J; Wang R Cell Death Dis; 2018 Feb; 9(2):220. PubMed ID: 29445162 [TBL] [Abstract][Full Text] [Related]
16. Clinical significance of MYCN amplification in patients with high-risk neuroblastoma. Lee JW; Son MH; Cho HW; Ma YE; Yoo KH; Sung KW; Koo HH Pediatr Blood Cancer; 2018 Oct; 65(10):e27257. PubMed ID: 29797634 [TBL] [Abstract][Full Text] [Related]
17. Thymidylate synthase inhibitor raltitrexed can induce high levels of DNA damage in MYCN-amplified neuroblastoma cells. Yamashita K; Kiyonari S; Tsubota S; Kishida S; Sakai R; Kadomatsu K Cancer Sci; 2020 Jul; 111(7):2431-2439. PubMed ID: 32415892 [TBL] [Abstract][Full Text] [Related]
18. MYCN protein stability is a better prognostic indicator in neuroblastoma. Yang Y; Zhao J; Zhang Y; Feng T; Yv B; Wang J; Gao Y; Yin M; Tang J; Li Y BMC Pediatr; 2022 Jul; 22(1):404. PubMed ID: 35820898 [TBL] [Abstract][Full Text] [Related]
19. Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk Wei JS; Kuznetsov IB; Zhang S; Song YK; Asgharzadeh S; Sindiri S; Wen X; Patidar R; Najaraj S; Walton A; Auvil JMG; Gerhard DS; Yuksel A; Catchpoole D; Hewitt SM; Sondel PM; Seeger R; Maris JM; Khan J Clin Cancer Res; 2018 Nov; 24(22):5673-5684. PubMed ID: 29784674 [No Abstract] [Full Text] [Related]
20. MYCN Amplification Is Associated with Reduced Expression of Genes Encoding γ-Secretase Complex and NOTCH Signaling Components in Neuroblastoma. Agarwal P; Glowacka A; Mahmoud L; Bazzar W; Larsson LG; Alzrigat M Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175848 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]